CDRS = Children's Depression Rating Scale, CGI = Clinical Global Impressions, NS = not significant, HAMD = Hamilton Depression Rating Scale. Fluoxetine First line a ≤11 yr, 5 mg/day; ≥12 yr ...
In a post-hoc analysis, cariprazine seemed to be effective in treating both depressive and manic episodes of bipolar I disorder across age groups.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
Medpage Today on MSN13d
Alzheimer's Pathology May Not Explain Links Between Cognitive Decline and DepressionHowever, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...
DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...
PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback